512 related articles for article (PubMed ID: 15690691)
21. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
22. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
Matsuura R; Soma M; Maeda Y; Kasakura S
Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037
[TBL] [Abstract][Full Text] [Related]
23. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
24. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
25. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma.
Semeraro N; Montemurro P; Giordano P; Santoro N; De Mattia D; Colucci M
Thromb Haemost; 1994 Jul; 72(1):54-7. PubMed ID: 7974375
[TBL] [Abstract][Full Text] [Related]
26. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
27. Effects of pegylated interferon α on fibrinolytic parameters in patients with chronic hepatitis C.
Gokmen A; Ustundag Y; Oztoprak N; Aydemir S; Tekin IO; Cakal B; Kiran S; Engin H
Clin Appl Thromb Hemost; 2011 Oct; 17(5):449-53. PubMed ID: 20699259
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
29. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
31. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the fibrinolytic system in myocardial infarction].
Moreno JA; Cornudella R; Gálvez M; Angós JA; Romero S; Gutiérrez M
Sangre (Barc); 1994 Feb; 39(1):23-7. PubMed ID: 8197514
[TBL] [Abstract][Full Text] [Related]
33. Novel distribution pattern of fibrinolytic components in rabbit tissues extract: a preliminary study.
Lu XG; Wu XG; Xu XH; Gong XB; Zhou X; Xu GB; Zhu L; Zhao XY
J Zhejiang Univ Sci B; 2007 Aug; 8(8):570-4. PubMed ID: 17657859
[TBL] [Abstract][Full Text] [Related]
34. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
Salobir B; Sabovic M; Zupan IP; Ponikvar JB
Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.
Rallidis LS; Megalou AA; Papageorgakis NH; Trikas AG; Chatzidimitriou GI; Tsitouris GK
Thromb Haemost; 1996 Sep; 76(3):417-21. PubMed ID: 8883280
[TBL] [Abstract][Full Text] [Related]
36. Natural anticoagulants and fibrinolytic activity following interferon therapy in chronic viral hepatitis.
Al Ghumlas AK; Abdel Gader AG; Al Faleh FZ
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):263-7. PubMed ID: 18469546
[TBL] [Abstract][Full Text] [Related]
37. [Fibrinolysis parameters: plasmin-alpha2 antiplasmin complexes (PAP) and D-dimers in acute coronary syndromes without ST segment elevation].
Grabarczyk E; Wodyńska T; Kotschy M
Pol Merkur Lekarski; 2004 Dec; 17(102):555-7. PubMed ID: 15771120
[TBL] [Abstract][Full Text] [Related]
38. Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Li F; Zhang G; Zhao W
Chin Med J (Engl); 2003 Mar; 116(3):475-7. PubMed ID: 12781064
[TBL] [Abstract][Full Text] [Related]
39. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
40. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
